Inspiration Biopharmaceuticals, a US-based company developing a treatment for blood disorders backed by France-based biotech firm Ipsen, has filed for chapter 11 bankruptcy and is about to hire an investment bank to manage a sale process.
Ipsen said it had provided $18.3m in debtor-in-possession financing to help manage disposition of Inspiration’s assets and faces a $153m write-off on the hemophilia drugs being developed by its portfolio company. However, the US Food & Drug Administration has delayed the development, pushing Inspiration…
